Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
Noura J ChoudhuryAdam J SchoenfeldJessica FlynnChristina J FalconHira RizviCharles M RudinMark G KrisMaria E ArcilaGlenn HellerHelena A YuMarc LadanyiGregory J RielyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
With better outcomes on platinum chemotherapy, patients with EGFR ex20ins NSCLC have improved prognosis, lower PD-L1 expression and TMB, and derive less benefit from ICIs compared with patients with NSCLC without targetable oncogenes. Improving molecularly targeted therapies could provide greater benefit for patients with EGFR ex20ins.